Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2008 1
2009 1
2012 2
2014 1
2015 1
2016 2
2017 10
2018 4
2019 2
2020 2
2021 3
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.
Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Dellas C, Duerschmied D, Empen K, Ferrari E, Galiè N, Jiménez D, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G. Konstantinides SV, et al. Among authors: bouvaist h. J Am Coll Cardiol. 2017 Mar 28;69(12):1536-1544. doi: 10.1016/j.jacc.2016.12.039. J Am Coll Cardiol. 2017. PMID: 28335835 Free article. Clinical Trial.
BACKGROUND: The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. ...RESULTS: Long-term (median 37.8 months) survival was assessed in 353 of 359 (98.3%) patients in the thrombolysis arm and in 343 of 350 (98.0%) in the placebo arm. .. …
BACKGROUND: The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. ...RESULTS: Long-term (media …
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.
Boucly A, Savale L, Jaïs X, Bauer F, Bergot E, Bertoletti L, Beurnier A, Bourdin A, Bouvaist H, Bulifon S, Chabanne C, Chaouat A, Cottin V, Dauphin C, Degano B, De Groote P, Favrolt N, Feng Y, Horeau-Langlard D, Jevnikar M, Jutant EM, Liang Z, Magro P, Mauran P, Moceri P, Mornex JF, Palat S, Parent F, Picard F, Pichon J, Poubeau P, Prévot G, Renard S, Reynaud-Gaubert M, Riou M, Roblot P, Sanchez O, Seferian A, Tromeur C, Weatherald J, Simonneau G, Montani D, Humbert M, Sitbon O. Boucly A, et al. Among authors: bouvaist h. Am J Respir Crit Care Med. 2021 Oct 1;204(7):842-854. doi: 10.1164/rccm.202009-3698OC. Am J Respir Crit Care Med. 2021. PMID: 34185620 Free article.
Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival of patients with PAH categorized according to the initial treatment strategy. ...
Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. …
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH; MERIT study investigators. Ghofrani HA, et al. Lancet Respir Med. 2024 Apr;12(4):e21-e30. doi: 10.1016/S2213-2600(24)00027-4. Lancet Respir Med. 2024. PMID: 38548406 Clinical Trial.
BACKGROUND: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar. ...
BACKGROUND: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thr …
Lympho-hematopoietic malignancies risk after exposure to low dose ionizing radiation during cardiac catheterization in childhood.
Abalo KD, Malekzadeh-Milani S, Hascoët S, Dreuil S, Feuillet T, Damon C, Bouvaist H, Bouzguenda I, Cohen S, Dauphin C, Di Filippo S, Douchin S, Godart F, Guérin P, Helms P, Karsenty C, Lefort B, Mauran P, Ovaert C, Piéchaud JF, Thambo JB, Lee C, Little MP, Bonnet D, Bernier MO, Rage E. Abalo KD, et al. Among authors: bouvaist h. Eur J Epidemiol. 2023 Jul;38(7):821-834. doi: 10.1007/s10654-023-01010-7. Epub 2023 May 16. Eur J Epidemiol. 2023. PMID: 37191831
Although radiation doses from a single CC are usually low, less is known about the long-term radiation associated cancer risks. We aimed to assess the risk of lympho-hematopoietic malignancies in pediatric CHD patients diagnosed or treated with CC. ...
Although radiation doses from a single CC are usually low, less is known about the long-term radiation associated cancer risks. We ai …
From evidence-based medicine to personalized medicine, with particular emphasis on drug-safety monitoring.
Ennezat PV, Cosgrove S, Bouvaist H, Maréchaux S, Guerbaai RA, Le Jemtel T, Andréjak M, Vital-Durand D. Ennezat PV, et al. Among authors: bouvaist h. Arch Cardiovasc Dis. 2017 Jun-Jul;110(6-7):413-419. doi: 10.1016/j.acvd.2017.01.011. Epub 2017 May 25. Arch Cardiovasc Dis. 2017. PMID: 28552224 Free article. Review.
Unfortunately, drug-safety monitoring is often overlooked in routine clinical practice. Finally, the lack of long-term therapeutic data (>5-10 years) is an unsolved dilemma, as most trials are limited to a duration of a few months or years....
Unfortunately, drug-safety monitoring is often overlooked in routine clinical practice. Finally, the lack of long-term therapeutic da …
Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2.
Mavromanoli AC, Barco S, Ageno W, Bouvaist H, Brodmann M, Cuccia C, Couturaud F, Dellas C, Dimopoulos K, Duerschmied D, Empen K, Faggiano P, Ferrari E, Galiè N, Galvani M, Ghuysen A, Giannakoulas G, Huisman MV, Jiménez D, Kozak M, Lang IM, Meneveau N, Münzel T, Palazzini M, Petris AO, Piovaccari G, Salvi A, Schellong S, Schmidt KH, Verschuren F, Schmidtmann I, Toenges G, Klok FA, Konstantinides SV; PEITHO-2 Investigators. Mavromanoli AC, et al. Among authors: bouvaist h. Clin Res Cardiol. 2023 Oct;112(10):1372-1381. doi: 10.1007/s00392-022-02138-4. Epub 2022 Dec 21. Clin Res Cardiol. 2023. PMID: 36539534 Free PMC article. Clinical Trial.
Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term....
Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term....
Value of brain MRI in infective endocarditis: a narrative literature review.
Champey J, Pavese P, Bouvaist H, Kastler A, Krainik A, Francois P. Champey J, et al. Among authors: bouvaist h. Eur J Clin Microbiol Infect Dis. 2016 Feb;35(2):159-68. doi: 10.1007/s10096-015-2523-6. Epub 2015 Nov 19. Eur J Clin Microbiol Infect Dis. 2016. PMID: 26585337 Free PMC article. Review.
The literature remains incomplete regarding the impact of MRI on concerted decision-making. The long-term prognosis of CMBs has not been evaluated to date and requires further studies. ...
The literature remains incomplete regarding the impact of MRI on concerted decision-making. The long-term prognosis of CMBs has not b …
Prognostic factors for extracorporeal cardiopulmonary resuscitation recipients following out-of-hospital refractory cardiac arrest. A systematic review and meta-analysis.
Debaty G, Babaz V, Durand M, Gaide-Chevronnay L, Fournel E, Blancher M, Bouvaist H, Chavanon O, Maignan M, Bouzat P, Albaladejo P, Labarère J. Debaty G, et al. Among authors: bouvaist h. Resuscitation. 2017 Mar;112:1-10. doi: 10.1016/j.resuscitation.2016.12.011. Epub 2016 Dec 19. Resuscitation. 2017. PMID: 28007504 Review.
The median prevalence of the primary outcome (i.e., short- or long-term survival for five studies and cerebral performance for ten studies) was 15% (range, 0-50%). ...
The median prevalence of the primary outcome (i.e., short- or long-term survival for five studies and cerebral performance for ten st …
Prevalence, therapeutic management and medium-term prognosis of spontaneous coronary artery dissection: results from a database of 11,605 patients.
Vanzetto G, Berger-Coz E, Barone-Rochette G, Chavanon O, Bouvaist H, Hacini R, Blin D, Machecourt J. Vanzetto G, et al. Among authors: bouvaist h. Eur J Cardiothorac Surg. 2009 Feb;35(2):250-4. doi: 10.1016/j.ejcts.2008.10.023. Epub 2008 Nov 28. Eur J Cardiothorac Surg. 2009. PMID: 19046896 Review.
OBJECTIVE: To assess the prevalence, clinical presentation, therapeutic management and medium-term prognosis of spontaneous coronary artery dissection (SCAD). ...
OBJECTIVE: To assess the prevalence, clinical presentation, therapeutic management and medium-term prognosis of spontaneous coronary …
Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome.
Danger R, Royer PJ, Reboulleau D, Durand E, Loy J, Tissot A, Lacoste P, Roux A, Reynaud-Gaubert M, Gomez C, Kessler R, Mussot S, Dromer C, Brugière O, Mornex JF, Guillemain R, Dahan M, Knoop C, Botturi K, Foureau A, Pison C, Koutsokera A, Nicod LP, Brouard S, Magnan A; COLT and SysCLAD Consortia. Danger R, et al. Front Immunol. 2018 Jan 11;8:1841. doi: 10.3389/fimmu.2017.01841. eCollection 2017. Front Immunol. 2018. PMID: 29375549 Free PMC article.
Bronchiolitis obliterans syndrome (BOS), the main manifestation of chronic lung allograft dysfunction, leads to poor long-term survival after lung transplantation. Identifying predictors of BOS is essential to prevent the progression of dysfunction before irreversible dama …
Bronchiolitis obliterans syndrome (BOS), the main manifestation of chronic lung allograft dysfunction, leads to poor long-term surviv …
27 results